INFU vs. AXGN, NPCE, SMLR, OM, CLPT, TMCI, NNOX, NYXH, ZIMV, and SMTI
Should you be buying InfuSystem stock or one of its competitors? The main competitors of InfuSystem include AxoGen (AXGN), NeuroPace (NPCE), Semler Scientific (SMLR), Outset Medical (OM), ClearPoint Neuro (CLPT), Treace Medical Concepts (TMCI), Nano-X Imaging (NNOX), Nyxoah (NYXH), ZimVie (ZIMV), and Sanara MedTech (SMTI). These companies are all part of the "medical equipment" industry.
InfuSystem vs. Its Competitors
AxoGen (NASDAQ:AXGN) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.
AxoGen currently has a consensus price target of $22.20, suggesting a potential upside of 127.69%. InfuSystem has a consensus price target of $13.00, suggesting a potential upside of 103.76%. Given AxoGen's higher probable upside, equities research analysts clearly believe AxoGen is more favorable than InfuSystem.
InfuSystem has a net margin of 1.12% compared to AxoGen's net margin of -7.91%. InfuSystem's return on equity of 2.78% beat AxoGen's return on equity.
InfuSystem has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
AxoGen has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.
In the previous week, AxoGen and AxoGen both had 2 articles in the media. AxoGen's average media sentiment score of 1.86 beat InfuSystem's score of 0.28 indicating that AxoGen is being referred to more favorably in the media.
80.3% of AxoGen shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 2.8% of AxoGen shares are owned by insiders. Comparatively, 11.4% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
AxoGen received 447 more outperform votes than InfuSystem when rated by MarketBeat users. However, 100.00% of users gave InfuSystem an outperform vote while only 72.93% of users gave AxoGen an outperform vote.
Summary
InfuSystem beats AxoGen on 11 of the 18 factors compared between the two stocks.
Get InfuSystem News Delivered to You Automatically
Sign up to receive the latest news and ratings for INFU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InfuSystem Competitors List
Related Companies and Tools
This page (NYSE:INFU) was last updated on 6/16/2025 by MarketBeat.com Staff
Buy INFU Stock Free INFU Stock Alerts